Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version

Mais informações no site da editora / Further information on publisher's website:
https://bmcmedgenet.biomedcentral.com/articles/10.1186/s12881-019-0899-3

DOI: 10.1186/s12881-019-0899-3

Direitos autorais / Publisher's copyright statement:
©2019 by Springer Nature. All rights reserved.
Uridine diphosphate glucuronosyl transferase 1A (UGT1A1) promoter polymorphism in young patients with sickle cell anaemia: report of the first cohort study from Nigeria

Oladele Simeon Olatunya 1,2*, Dulcineia Martins Albuquerque 1, Ganiyu Olusola Akanbi 3, Olufunso Simisola Aduayi 3, Adekunle Bamidele Taiwo 4, Opeyemi Ayodeji Faboya 5, Tolorunju Segun Kayode 6, Daniela Pinheiro Leonardo 1, and Fernando Ferreira Costa 1

Abstract

Background: (TA) n repeat sequence (rs8175347) of UGT1A1 gene promoter polymorphism is associated with serum bilirubin levels and gallstones among different sickle cell anaemia (SCA) populations. There are no data on UGT1A1 polymorphisms and their impact on Nigerian SCA patients. In this study, we determined the distribution of the UGT1A1 (TA) n genotypes among a group of young Nigerian SCA patients and healthy controls. In addition, the influence of UGT1A1 (TA) n genotypes on the laboratory and clinical events among the patients was determined.

Methods: The distribution of the UGT1A1 (TA) n genotypes among 101 young Nigerian SCA patients and 64 normal appropriate controls were determined and studied. The UGT1A1 (TA) n genotypes were further classified into subgroups and used to differentiate the clinical events and laboratory parameters of the patients.

Results: Four (TA) n alleles: (TA)5, 6, 7, and 8 were found. These were associated with 10 genotypes: TA5/5, 5/6, 5/7, 5/8, 6/6, 6/7, 6/8, 7/7, 7/8, 8/8. The normal (wild-type) (TA) 6/6), low-(TA) 7/7, 7/8, 8/8), intermediate- (TA) 5/7, 5/8, 6/7, 6/8), and high-activity (TA) 5/5, 5/6), genotypes were found in 24.8, 24.8, 41.5, and 8.9% patients and 20.3, 15.6, 61, and 3.1% controls respectively. The general genotype distribution of the patients and control group were not significantly different. There were significant differences in serum bilirubin and lactate dehydrogenase (LDH) of the patients when differentiated by the UGT1A1 (TA) n genotypes (p<0.05). Asymptomatic gallstones were found in 5.9% of patients and were significantly of the low-activity genotypes sub-group 5 (20%) vs 1(1.3%) p = 0.0033. Although, bilirubin and fetal hemoglobin (HbF) of patients with gallstones were significantly different from those without gallstone, only the serum bilirubin was associated with UGT1A1 (TA) n genotypes on multivariate analysis (p < 0.0001).

Conclusion: This study highlights the contribution of UGT1A1 polymorphisms, a non-globin genetic factor, to the laboratory and clinical manifestations of young Nigerian SCA patients for the first time. It also shows that children with co-inheritance of low UGT1A1 (TA) n affinity genotypes may be at risk of gallstone, hence the need to follow them up.

Keywords: Sickle cell anaemia, Laboratory parameters, Clinical events, Gallstone, UGT1A1 polymorphism, Nigeria

* Correspondence: ladeletunya@yahoo.com; simeon.olatunya@eksu.edu.ng
1Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP), Rua Carlos Chagas, 480, Barão Geraldo, Campinas, SP 13083-970, Brazil
2Department of Paediatrics, College of Medicine, Ekiti State University, Ado Ekiti, Ekiti State, Nigeria
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Sickle cell disease (SCD) is a common genetic disorder among Africans. Individuals with the disease have variable clinical expression but homozygosity for the HbS gene, also known as sickle cell anaemia (SCA), is the most severe form [1]. Children with SCA have chronic hemolysis, leading to accumulation of serum bilirubin and consequent gallstones [2]. Bilirubin is a tetrapyrrole that results from the breakdown of heme in red blood cells. At moderate levels, it protects against oxidative stress and inflammatory injuries, and some infectious diseases [3–5]. However, excessive bilirubin levels, as seen in chronic hemolysis, have been linked to increased incidence of gallstones [1, 2, 5]. In children with SCA, this risk increases with advancing age with a cumulative incidence of approximately 50% by adulthood and some of them may need cholecystectomy [2, 6, 7].

Uridine diphosphate glucuronosyltransferase 1A isoform 1 (UGT1A1) is a member of the superfamily of phase II conjugating enzymes that aids the elimination of bilirubin, drugs and a vast variety of endogenous and exogenous substrates by adding a glucuronic moiety to the substrates [8, 9]. Genetic mutations resulting in absence or severely reduced UGT1A1 activity leads to Criggler-Najjar syndrome which is characterized by severely elevated serum bilirubin and increased risk of kernicterus [10]. However, variations in (TA) n tandem repeat sequence within the TATA box promoter region affect UGT1A1 gene expression and the activity of its (TA) n four alleles, namely; (TA) 5, 6, 7, and 8, leading to moderate elevation of serum bilirubin [8, 9]. There is a negative association between the UGT1A1 and repeat length of the four alleles attributable to the decreasing promoter activity acting via altered affinity for the TATA–binding protein [8, 9]. The promoter activity leads to functional changes such that, genotype (TA)5/5 is considered to have ~ 20% increased expression i.e. high activity in comparison to genotype (TA) 6/6 known as the wild-type with normal activity. In addition, genotypes heterozygous and or homozygous for (TA)7 and (TA)8 alleles have approximately between 30 and 50% reduced expression i.e. low activity, compared to the wild-type [8]. However, genotypes (TA)7/7, 7/8 & 8/8 have the lowest activity [2, 8, 9] and (TA)7/7 has been described generally as genetic hallmark for Gilbert syndrome [2, 11]. There is an inverse relationship between the serum bilirubin levels across these subgroups and the degree of genotype activity. To this end, individuals with low-activity genotypes have elevated levels of serum bilirubin and are, therefore, subjected to the modulating effects of higher serum bilirubin levels including susceptibility to gallstones [2, 8, 9, 11].

Despite the huge burden of SCA in Africa [1], with Nigeria having the highest burden of SCA in the world [12], there is little understanding of the contributions of genetic modifiers of SCA phenotypes in the country. To the best of our knowledge, there are no data on the effects of UGT1A1 polymorphisms on the clinical expression of Nigerian SCA patients. The aims of this study were to determine the distribution of UGT1A1 (TA) n genotypes among a group of young SCA patients and healthy controls and also determine the influence of the UGT1A1 (TA) n genotypes on the laboratory parameters and clinical events among the young SCA patients.

Methods
Study participants and settings
The study was conducted on 101 hydroxyurea-naïve children and adolescents with SCA (Homozygous SS) aged between 2 and 21 years (median of 9 years) who are regular attendees at the paediatric haematology unit of the Ekiti State University Teaching Hospital (EKSGUTH), Ado Ekiti, Ekiti State, in Southwest Nigeria. They were all in steady state at the time of recruitment. Steady state was defined as being free from any acute event(s) for at least 1 month and transfusion free for at least 4 months. Sixty four genetically independent and unrelated children, who accompanied their siblings to or attended the paediatrics outpatients’ well-child clinic of the hospital served as the controls. Participants with confirmed or suspected liver or other chronic diseases apart from SCA were excluded. Also excluded were the few SCA patients on regular blood transfusion and/or hydroxyurea.

Ethical approval
The study was approved by the Ethics and Research Committee of EKSGUTH no: A67/2016/03/003. Because the DNA analysis was done at the hematology and hemotherapy centre, University of Campinas, the study was also approved by the University of Campinas Ethics Committee no: CAAE 54031115.9.0000.5404. Written informed consent of parents/caregivers as well as patients’ assents and consents were obtained as applicable after explaining the purpose of the study to them in clear and plain language.

Data collection
Clinical and laboratory data
Information regarding the steady-state laboratory parameters and clinical events of the patients were retrieved from their hospital records. Average of at least two steady state results of laboratory parameters performed between 3 to 6 months intervals by standard techniques were recorded for each participant. The steady state parameters included the complete blood performed by Sysmex KX21N Hematology analyser (Sysmex Corporation, Kobe, Japan). The serum lactate dehydrogenase (LDH), bilirubin, were measured with standard techniques. The quantitative assessment of haemoglobin pattern (HbF and HbS), was done by high
Other information retrieved from patients’ charts included the biodata and details of the clinical evolution of SCA such as number of vaso-occlusive crisis (VOC) i.e. severe bone pain crises that disrupt daily activities and required admission and/or administration of opioids within the preceding 1 year, leg ulcer, priapism, overt osteonecrosis and/or overt stroke as well as presence of gallstone as determined by serial abdominal ultrasound scans conducted on the patients as clinically indicated. In addition, the clinical records of the patients with gallstones were examined for the presence or absence of symptoms, and or treatment(s) for gallstone complications. The definitions of clinical events were as previously described [13].

**Genetic studies**

These were carried out at the Centro de Hematologia e Hemoterapia (Hemocentro), UNICAMP, Campinas, São Paulo State, Brazil. SCA was initially diagnosed by haemoglobin electrophoresis and high performance liquid chromatography (HPLC) in Nigeria.

The genomic DNA of each participant was extracted from peripheral blood leukocytes by Qiagen QIAamp DNA Blood Mini Kit, (Cat No. 51104 Germany), according to the manufacturer’s protocols and used to confirm the molecular diagnosis of SCD by polymerase chain reaction (PCR). The DNA purity and concentration were evaluated on Nanodrop ND-1000® Spectrophotometer (NanoDrop Technologies, Inc., DE, USA). PCR for exon 1 of HBB gene amplification was performed according to the following protocol in 30 μL volume: 150 ng of genomic DNA; 1X Colorless GoTaq® Flexi Reaction Buffer (Promega Corporation, Madison, USA); 2 mM MgCl₂; 0.2 mM of dNTP mix; 0.2 μM of each primer (Integrated DNA Technologies, Coralville, Iowa) named P1: TCCTAAGCCAGTGC CAGAAG and P5: TCATTCGTCTGTTTCCCATTC [14] and 1 U of GoTaq® Flexi DNA Polymerase (Promega Corporation, Madison, USA). Thermal cycle conditions were as follow: preheating at 96 °C by 2 min, followed by 25 cycles of 96 °C for 30 s, 58 °C for 40 s, and 72 °C for 40 s. An ended step at 72 °C for 30 min was performed to promote adenylation of the PCR products. Fragment analysis was performed by Capillary electrophoresis on ABI3500 Genetic Analyzer and sizes of amplicons were calculated with Gene Mapper v.4.1 Software (both Applied Biosystems, Carlsbad, CA) - the fragments ranged from 197 to 203 bp, corresponding to (TA)₅ -(TA)₈ repeats (Additional file 1: Figure S1). Based on literature data, the UGT1A1 (TA)ₙ genotypes were further classified into four subgroups namely: Wild-type (normal), low-, intermediate-, and high-activity subgroups as previously described [2, 8, 9, 11]. All DNA studies were carried out blinded regardless of the clinical and laboratory parameters of the participants.

**Data analysis**

Statistical analysis was performed with the GraphPad Prism Program, version 5 for Windows (San Diego, California, USA). The normal distribution of the quantitative variables was verified by the Kolmogorov-Smirnov and Shapiro-Wilk tests. The frequencies of variables were described and the significance of differences between quantitative variables across groups of patients was assessed using the Kruskal-Wallis analysis of variance (ANOVA) for ≥3 groups, and Mann-Whitney test for two groups. Chi-square or Fisher’s exact tests were used as appropriate for the categorical variables. Odd ratios were obtained by applying logistic regression to determine the effects of UGT1A1 promoter polymorphism using the UGT1A1 (TA)ₙ genotype as the independent variable and other outcomes of interest as the dependent variables. The test for Hardy-Weinberg equilibrium was performed using the R-Project for statistical computing web tool available at [https://www.R-project.org](https://www.R-project.org). Level of significance was set at \( P < 0.05 \) for all statistical analyses.

**Results**

The 101 patients with SCA consisted of 66 males and 35 females with median age of 9 and a range 2 - 21 years.
The controls were made up of 19 sickle cell trait (HbAS) and 45 haemoglobin HbAA, median age of 8, range 2 - 18 years ($p = 0.4260$), and 41 males. The SCA patients have been on follow up for a median of 4 years, range 1–14 years.

**UGT1A1 (TA) n alleles and genotypes**

Four (TA) n alleles: (TA)5, 6, 7, and 8 were found with gene frequencies of 0.11, 0.43, 0.41 and 0.05 respectively. The alleles were associated with 10 genotypes: TA5/5, 5/6, 5/7, 5/8, 6/6, 6/7, 6/8, 7/7, 7/8, 8/8 (Table 1). The wild-type (normal) (TA) 6/6, low (TA) 7/7, 7/8, 8/8, intermediate (TA) 5/7, 5/8, 6/7, 6/8, and high (TA) 5/5, 5/6, enzyme activity genotypes were found in 24.8, 24.8, 41.5%, & 8.9% patients and 20.3, 15.6, 61%, & 3.1% controls respectively. The low activity genotypes were found in 25 (24.7%) patients and 10 (15.6%) of the controls ($P = 0.1773$). Homozygous (TA) n TA7/7 was found in 22 (21.7%) patients and 5 (7.8%) controls $p = 0.018$ (Table 1). The observed genotype distributions of the patients and control group were not significantly different from the values expected under Hardy-Weinberg equilibrium ($\chi^2 = 15.10, df = 9, P = 0.09$), and ($\chi^2 = 11.86, df = 9, P = 0.22$), respectively.

**Effects of UGT1A1 genotype on serum bilirubin and other laboratory parameters of patients**

Both the total bilirubin and unconjugated bilirubin levels showed distinct quantitative patterns across the UGT1A1 (TA) n genotype subgroups with the low-activity genotype group having the highest levels of serum bilirubin ($p < 0.0001$). The LDH also showed a similar pattern ($p = 0.0002$). However, this was not demonstrated in the other laboratory parameters (Table 2). The stratification of the individual UGT1A1 (TA) n genotypes separately shows that (TA)7 and (TA) 8 alleles were associated with higher levels of both serum bilirubin and LDH in general (Additional file 2: Table S1).

**Effects of UGT1A1 (TA) n genotype on clinical events**

Asymptomatic gallstones were found in 6 (5.9%) patients. Gallstones were significantly more common in patients with low-activity genotypes compared to all the other remaining genotype subgroups 5 (20%) vs 1(1.3%) $p = 0.0033$, (Table 3). These were 2 females and 4 males; the two females were aged 10 and 13 years respectively, while the males were aged 10, 13, 15 and 16 years respectively. Four of the patients with gallstone had TA 7/7 genotypes, the remaining two each had TA 7/8, or TA

| Table 1 Allele and genotype frequencies of UGT1A1 promoter polymorphisms among participants |
|-----------------------------------------------|------------------|------------------|------------------|
| Variables                                      | SCA (N = 101)    | AS (N = 19)      | AA (N = 45)      |
| Allelotypes                                    | Freq n (%)       | Freq n (%)       | Freq n (%)       |
| (TA) 5                                         | 18 (11.7)        | 2 (6.7)          | 10 (21.7)        |
| (TA)6                                          | 67 (43.5)        | 16 (53.3)        | 28 (35.0)        |
| (TA)7                                          | 61 (39.6)        | 10 (33.3)        | 37 (46.2)        |
| (TA)8                                          | 8 (5.2)          | 2 (6.7)          | 5 (6.3)          |
| UGT1A1 Genotypes                               |                  |                  |                  |
| TA5/5                                          | 0 (0)            | 0 (0)            | 1 (2.2)          |
| TA5/6                                          | 9 (8.9)          | 0 (0)            | 1 (2.2)          |
| TA5/7                                          | 6 (6.0)          | 1 (5.2)          | 8 (17.7)         |
| TA5/8                                          | 3 (2.9)          | 0 (0)            | 0 (0)            |
| TA6/6                                          | 25 (24.7)        | 8 (42.1)         | 5 (11.1)         |
| TA6/7                                          | 31 (30.7)        | 7 (36.8)         | 21 (46.7)        |
| TA6/8                                          | 2 (2.0)          | 1 (5.2)          | 1 (2.2)          |
| TA7/7                                          | 22 (21.7)        | 1 (5.2)          | 4 (8.9)          |
| TA7/8                                          | 2 (2.0)          | 1 (5.2)          | 4 (8.9)          |
| TA8/8                                          | 1 (1.0)          | 0 (0)            | 0 (0)            |
| UGT1A1 Genotypes by degree of Activity         |                  |                  |                  |
| Low-Activity genotypes TA (7/7, 7/8, 8/8)      | 25 (24.8)        | 2 (10.5)         | 8 (17.8)         |
| Intermediate-Activity genotypes (TA6/7, TA6/8, TA5/7, TA5/8, TA8/8) | 42 (41.5) | 9 (47.4) | 30 (66.7) |
| Normal Activity genotypes i.e. (Wild Type) TA6/6 | 25 (24.8) | 8 (42.1) | 5 (11.1) |
| High-Activity genotypes TA5/5, TA5/6, TA6/6    | 9 (8.9)          | 0 (0)            | 2 (4.4)          |
No significant relationship was found with the other clinical events.

Comparison of laboratory parameters between patients with and without gallstones
There were significant differences between the serum bilirubin and HbF levels in patients with gallstones when compared with those without. No difference was observed in the LDH and age of the two groups. Furthermore, when those with gallstones were compared with age- and sex-matched patients within the same UGT1A1 (TA) n genotype subgroup, only serum bilirubin and HbF showed significant differences between the two groups (Table 4).

Table 2 Influence of UGT1A1 (TA) n genotype on laboratory parameters of patients

| Parameter | a. Low activity UGT1A1 genotypes N = 25 | b. Intermediate activity UGT1A1 genotypes N = 42 | c. Normal activity UGT1A1 genotypes (i.e Wild type) N = 25 | d. High activity UGT1A1 genotypes N = 9 | Anova (Kruskal-Wallis Test) P values (a vs b vs c vs d) |
|-----------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Biochemical and hematologic | Median (Range) | Median (Range) | Median (Range) | Median (Range) | < 0.0001*** 1 |
| Total Bilirubin (mg/dl) | 2.8 (1.2–8.1) | 1.8 (0.8–4.6) | 1.4 (0.4–3.8) | 1.4 (0.5–2.8) | < 0.0001*** 1 |
| Unconjugated Bilirubin (mg/dl) | 1.8 (0.6–6.3) | 0.8 (0.1–3.3) | 0.6 (0.1–2.3) | 0.5 (0.3–1.6) | < 0.0001*** 1 |
| LDH (IU/L) | 987 (296–1860) | 798 (215–1489) | 789 (340–1417) | 287 (197–800) | 0.0002** |
| AST (IU/L) | 46 (18–89) | 37 (8–89) | 42 (7–89) | 39 (18–89) | 0.4837** |
| ALT (IU/L) | 7.3 (6.3–10) | 7.5 (6.3–9.7) | 7.2 (6.2–10) | 7.9 (7–8.8) | 0.608** |
| Hb conc (g/dl) | 80.6 (66.9–104.1) | 82.3 (60.3–102.2) | 77.3 (63.9–96.3) | 81 (55.9–115) | 0.642** |
| MCV (fl) | 80 (10–39) | 82 (44–91.5) | 80 (44–88.3) | 81 (65–89) | 0.096** |
| RBC (× 10 12/L) | 2.7 (1.9–4.1) | 2.7 (1.8–4.1) | 2.9 (1.8–4.8) | 2.8 (2.2–3.9) | 0.250** |
| WBC (× 10 9/L) | 2.6 (1.3–20.6) | 2.6 (1.3–20.6) | 2.6 (1.3–20.6) | 2.6 (1.3–20.6) | 0.955** |
| Platelet (× 10 9/L) | 367 (118–771) | 349 (159–601) | 361 (108–669) | 391 (135–832) | 0.3147** |
| HbF (%) | 9.7 (1.3–20.6) | 8.2 (1.3–20.6) | 10.7 (2.5–32) | 9.4 (0.9–28.5) | 0.86** |
| HbS (%) | 80 (71–91.5) | 80 (71–91.5) | 80 (71–91.5) | 80 (71–91.5) | 0.00033** |
| HbA2 (%) | 1.6 (0.5–3.5) | 1.7 (0.2–3.8) | 1.5 (0.2–4.0) | 1.1 (0.3–3.1) | 0.3147** |

Significant p values are indicated in bold fonts
HbF Fetal hemoglobin, RBC Red blood cell, HB Hemoglobin concentration, HbS Hemoglobin S, HbA2 Hemoglobin A2, MCV Mean corpuscular volume, WBC White blood cell count, LDH Lactate dehydrogenase, AST Aspartate transaminase, ALT Alanine transaminase
** = Kruskal-Wallis Test with Dunn’s multiple comparison post-hoc tests with differences in *1 = (a vs b), (a vs c), (a vs d) only; *2 = (a vs d), (b vs d), (c vs d) only

Table 3 Influence of UGT1A1 (TA) n genotype on clinical events of patients

| Clinical events | a. Low activity UGT1A1 genotypes N = 25 | b. Intermediate activity UGT1A1 genotypes N = 42 | c. Normal activity UGT1A1 genotypes (Wild Type) N = 25 | d. High activity UGT1A1 genotypes N = 9 | P value a vs (b + c + d) |
|----------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| VOC rate per year | 2 (0–6) | 1.5 (0–6) | 1 (0–6) | 0 (0–6) | 0.2218* |
| Overt Stroke | 1 | 2 | 1 | 0 | 1.000† |
| No overt stroke | 24 | 40 | 24 | 9 | 0.250** |
| Osteonecrosis | 1 | 2 | 2 | 0 | 1.000† |
| No osteonecrosis | 24 | 40 | 23 | 9 | 0.331† |
| Leg ulcer | 0 | 2 | 4 | 0 | 0.331† |
| No Leg ulcer | 25 | 40 | 21 | 9 | 0.0033† |
| Gallstones | 5 | 1 | 0 | 0 | 0.594† |
| No Gallstone | 20 | 41 | 25 | 9 | |
| Priapism (Male only event, N = 66) | 2 | 3 | 0 | 0 | 0.594† |
| Priapism | 0 | 0 | 0 | 0 | 0.594† |
| No Priapism | 15 | 25 | 16 | 5 | |

Significant p values are indicated in bold fonts
VOC Vaso-occlusive crisis
* = Mann-Whitney Test, † = Fisher’s exact test
Relationship between UGT1A1 (TA) n genotypes and other parameters by multivariate analysis

Unconjugated bilirubin was significantly associated with the low activity UGT1A1 (TA) n genotypes (Adjusted Odd Ratio (1.08), 95% Confidence interval (1.034768–1.127873), \( P < 0.0001 \)). Also, significant association was found with the total bilirubin when it was used in place of unconjugated bilirubin in the logistic regression model (Adjusted Odd Ratio (1.05), 95% Confidence interval (1.029172–1.089832), \( P < 0.0001 \)). No association was found with the other laboratory parameters.

Discussion

There are gaps in the understanding of the impacts of genetic modifiers on SCA phenotype among African patients. Given the distinct segregation of genetic markers among different populations, it is pertinent that more studies are carried out among diverse ethnic cohorts to fully understand the impact of genetic polymorphisms in SCA.

This study confirms the variability of bilirubin levels based on the activity of the UGT1A1 (TA) n genotypes as previously reported [2, 4, 5, 8, 9]. However, we are not aware of any previous study that has described the stratification of LDH among SCA patients based on UGT1A1 (TA) n genotype activity as found in this study. While the UGT1A1 modulation of serum bilirubin levels is well understood [2, 17, 18], the exact mechanism through which UGT1A1 could be associated with LDH is not clear. However, it should be noted that they are both markers of hemolysis [19]. Given the association of LDH with some phenotypes of SCA [19, 20], there is need to further unravel the link between LDH and UGT1A1 activity.

Gilbert syndrome (GBS) has been described in individuals with the TA7/7 genotype [2, 4, 11, 17]. The proportion of patients with TA7/7 genotype in this study (21.7%) is higher than between 3 and 18% described among Europeans [21, 22] and Brazilians of different descents [23–25]. Similarly, it is higher than the 6% found among Kuwaiti SCA patients [26] and the 5 to 11% among other Africans [11, 22]. However, it is lower than the 32% described among the SCA patients in the USA [27]. Nevertheless, the TA7/7 genotype prevalence in this study, is comparable to between 18.2 and 20.3% earlier described among Nigerians with non-SCD related illnesses [28, 29]. However, the higher preponderance of TA7/7 among the patients compared to the controls in the present study is not clear but may be due to the low sample size.

Besides the TA7/7 genotype, the other UGT1A1 (TA) n genotypes found in this study have been described among Africans [9, 22]. These observations indicate that the UGT1A1 (TA) n genotype is quite variable among Nigerians. It also confirms the suggestions that the expression of the UGT1A1 (TA) n genotype variants is heterogeneous among Africans compared to Caucasians [9, 21, 22].

Our finding that the low-activity UGT1A1 (TA) n genotype was associated with gallstones confirms previous observations that SCA patients with the low-activity UGT1A1 (TA) n genotypes especially the TA7/7, are at

### Table 4 Comparison of parameters in patients with and without gallstones

| Parameter                        | Patients with gallstones (N = 6) Median (Range) | Patients without gallstones (N = 95) Median (Range) | P value |
|----------------------------------|-----------------------------------------------|---------------------------------------------------|---------|
| Total Bilirubin (mg/dl)          | 6.4 (2.8–8.1)                                 | 1.8 (0.4–6.7)                                     | 0.0001* |
| Unconjugated Bilirubin (mg/dl)   | 4.7 (0.9–6.3)                                 | 0.79 (0.1–5)                                      | 0.0007* |
| LDH (IU/L)                       | 1004 (592–1860)                               | 794 (197–1750)                                    | 0.1263* |
| HbF (%)                          | 4.7 (1.3–6.8)                                 | 10.2 (0.9–32)                                     | 0.0107* |
| Hb (g/dl)                        | 7.1 (6.3–8.8)                                 | 7.5 (6.2–10)                                      | 0.0421* |
| Age in years                     | 11.5 (8–16)                                   | 9 (2–21)                                          | 0.1368* |
| Sex                              |                                               |                                                   |         |
| Male (n = 66)                    | 4                                             | 62                                                | 1.000†  |
| Female (n = 35)                  | 2                                             | 33                                                |         |
| Parameter                        | Patients with gallstones (N = 6) Median (Range) | Matched peers without gallstones within same UGT1A1 genotype activity group N = 10 Median (Range) | P value |
| Total Bilirubin (mg/dl)          | 6.4 (2.8–8.1)                                 | 2.2 (1.9–3.2)                                     | 0.0023* |
| Unconjugated Bilirubin (mg/dl)   | 4.7 (0.9–6.3)                                 | 1.2 (1.0–2.0)                                     | 0.0020* |
| LDH (IU/L)                       | 1004 (592–1860)                               | 890 (340–1603)                                    | 0.0628* |
| HbF (%)                          | 4.7 (1.3–6.8)                                 | 14.7 (4.2–179)                                    | 0.022*  |
| Hb (g/dl)                        | 7.1 (6.3–8.8)                                 | 8.0 (6.5–8.9)                                     | 0.137*  |

NB Significant P values are indicated in bold fonts

HbF Fetal hemoglobin, Hb Hemoglobin concentration, LDH Lactate dehydrogenase

* = Mann-Whitney test, † = Fisher’s Exact test
risk of developing gallstones [2, 6, 7, 11, 17]. In addition to the TA7/7 genotype, other authors [11, 30], have reported that some other low-activity UGT1A1 (TA) n genotypes like TA7/8 and TA8/8 predispose SCA patients to gallstones as found in this study.

The proportion of patients with asymptomatic gallstones in this study (5.9%), is comparable to between 4 and 6% earlier reported among Nigerian children of similar age to our SCA cohorts [31–33]. This is also similar to the 4% found in Ghana [34], a close neighbour to Nigeria. However, it is lower than between 9 and 58% reported for some other African [35–37], Italian [38], American [39], and Brazilian [40] patients. These observations possibly highlight the variations in propensity to gallstone development among children with SCA from different backgrounds.

Despite the observation that the UGT1A1 (TA) n low-activity genotype is a leading factor in hyperbilirubinemia and lithogenesis among SCA patients [2, 6, 7, 41, 42], the impact of UGT1A1 polymorphism on the phenotypic expression of the Nigerian SCA patients was unknown prior to this study as none of the previous studies from Nigeria examined the UGT1A1 of the patients [31–33]. There is therefore, the need to closely follow up these patients given that, results of follow-up studies have indicated higher prevalence of gallstones and its complications with increasing age of SCA patients [2, 26, 30, 37, 40].

Beyond bilirubin metabolism and gallstone metabolism, it has been speculated that individuals with the low-activity genotypes may be subjected to some other modulating effects of higher serum bilirubin levels that are often associated with these genotypes [2, 8, 9, 11]. These other modulating effects include protection against oxidative stress, inflammatory injuries, and reduced susceptibility to infections [2–5, 8, 9, 43]. We did not observe any association between the UGT1A1 (TA) n genotypes and any of the other SCA downstream events/phenotypes examined (VOC, leg ulcer, priapism, overt stroke and osteonecrosis) that could be perturbed by both inflammatory and oxidative injuries in SCA. However, the small sample size of the study makes it difficult to draw any firm conclusion.

The major limitations of the present study are its hospital-based nature and the small sample. Despite these, it was able to confirm that UGT1A1 (TA) n genotypes are tightly associated with bilirubin and LDH levels, and the development of gallstones among young Nigerians with SCA. In addition, it also suggests that the pathway to elevated serum bilirubin and gallstone development, among our study cohort, may not be exclusively driven by hemolysis but also by UGT1A1 polymorphisms.

**Conclusions**

This study shows that children with co-inheritance of low UGT1A1 (TA) n affinity genotypes may be at risk of gallstone, thus highlighting the need to closely follow them up for early identification of possible gallstone complications and provision of appropriate intervention(s). In addition, it highlights the contribution of UGT1A1 polymorphisms, a non-globin genetic factor, to the laboratory and clinical manifestations of young Nigerian SCA patients for the first time.
Author details
1. Hematology and Hemotherapy Center (Hemocentro), University of Campinas (UNICAMP), Rua Carlos Chagas, 480, Barão Geraldo, Campinas, SP 13083-970, Brazil. 2. Department of Paediatrics, College of Medicine, Ekiti State University, Adebisi, Akiti State, Nigeria. 3. Department of Radiology, College of Medicine, Ekiti State University, Adebisi, Akiti State, Nigeria. 4. Department of Paediatrics, Ekiti State University Teaching Hospital, Adebisi, Akiti State, Nigeria. 5. Department of Medical Biochemistry, College of Medicine, Ekiti State University, Adebisi, Akiti State, Nigeria. 6. Department of Paediatrics, Faculty of Medicine, Kuwait University, Jabiya, Kuwait.

Received: 16 April 2019 Accepted: 30 September 2019
Published online: 16 October 2019

References
1. Rees DC, Williams TN, Gladwin MT. Sickle cell disease. Lancet. 2010;376:2018–31.
2. Carpenter SL, Siefert S, Howard TA, Eggleston B, Ware RE. UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell disease. Am J Hematol. 2008;83(10):800–3.
3. Stocker R, Yamamoto Y, McDonagh A, Glazer A. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043–6.
4. Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell disease. Clin Genet. 2003;64:160–2.
5. Italia KY, Jijina FF, Jain D, Merchant R, Nadkarni AH, Mukherjee M, et al. The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxycurea therapy in haemoglobinopathies. Clin Biochem. 2010;43:1329–32.
6. Horsfall LJ, Zeitlyn D, Tarekegn A, Bekele E, Thomas MG, Bradman N, et al. Prevalence of UGT1A1 gene polymorphism in patients with haemolytic anaemia in southern Brazil. Genet Test Mol Biomarkers. 2011;15(12):107–10.
7. Alfaridh S, Al-Jafer H, Hadi M, Al-Mutairi M, Nizam R. The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients. PLoS One. 2013;8(10):e77681. https://doi.org/10.1371/journal.pone.0077681.
8. Kadakol A, Ghosh SS, Sappal BS, et al. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Criggler-Najjar syndromes: correlation of genotype to phenotype. Hum Genet. 2010;126:113–21.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.